Validation of miRNA prognostic significance in stage II colorectal cancer: A protocol for systematic review and meta-analysis of observational clinical studies.
Shanthi Sabarimurugan,Chellan Kumarasamy,Madhav Madurantakam Royam,Kartik Lakhotiya,Gothandam Kodiveri Muthukaliannan,Suja Ramalingam,Rama Jayaraj +6 more
Reads0
Chats0
TLDR
Based on the systematic review and meta-analysis results of this study, the possible miRNAs could be predicted toward the prognosis of stage II colorectal cancer, and specific miRNAAs may perhaps be considered as a biomarker and therapeutic target for this malignancy.About:
This article is published in Medicine.The article was published on 2019-03-01 and is currently open access. It has received 3 citations till now.read more
Citations
More filters
Journal ArticleDOI
Oncogenesis and Tumor Inhibition by MicroRNAs and its Potential Therapeutic Applications: A Systematic Review.
Maryam Karkhane,Hamed Esmaeil Lashgarian,Maryam Hormozi,Shirzad Fallahi,Kourosh Cheraghipour,Abdolrazagh Marzban +5 more
TL;DR: The last global knowledge and concepts regarding the involvement of microRNAs in cancer emergence, which has been achieved from the previous studies, consisting of the regulation of key cancer-related pathways, such as cell cycle control and the DNA damage response and the disruption of profile expression in human cancer are achieved.
Journal ArticleDOI
Diagnostic and Prognostic Significance of MiR-150 in Colorectal Cancer: A Systematic Review and Meta-Analysis.
TL;DR: The present study findings suggest that miR-150 has high specificity and sensitivity values as a potential diagnostic biomarker in colorectal cancer patients, while the prognostic value of mi R-150 was not statistically significant.
Journal ArticleDOI
Prognostic Value of MicroRNAs in Stage II Colorectal Cancer Patients: A Systematic Review and Meta-Analysis
Shanthi Sabarimurugan,Madurantakam Royam Madhav,Chellan Kumarasamy,Ajay Gupta,Siddharta Baxi,Sunil Krishnan,Rama Jayaraj +6 more
TL;DR: MicroRNAs play a significant role in determining prognosis in stage II CRC patients, with upregulation of miR21, miR215, mi R143-5p and miR106a, in particular, portending a worse prognosis.
References
More filters
Journal ArticleDOI
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
TL;DR: Moher et al. as mentioned in this paper introduce PRISMA, an update of the QUOROM guidelines for reporting systematic reviews and meta-analyses, which is used in this paper.
Journal ArticleDOI
Measuring inconsistency in meta-analyses
TL;DR: A new quantity is developed, I 2, which the authors believe gives a better measure of the consistency between trials in a meta-analysis, which is susceptible to the number of trials included in the meta- analysis.
Journal ArticleDOI
Bias in meta-analysis detected by a simple, graphical test
TL;DR: Funnel plots, plots of the trials' effect estimates against sample size, are skewed and asymmetrical in the presence of publication bias and other biases Funnel plot asymmetry, measured by regression analysis, predicts discordance of results when meta-analyses are compared with single large trials.
Journal ArticleDOI
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
TL;DR: A structured summary is provided including, as applicable, background, objectives, data sources, study eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, conclusions and implications of key findings.
Journal ArticleDOI
Quantifying heterogeneity in a meta‐analysis
TL;DR: It is concluded that H and I2, which can usually be calculated for published meta-analyses, are particularly useful summaries of the impact of heterogeneity, and one or both should be presented in publishedMeta-an analyses in preference to the test for heterogeneity.